Neutropenic events associated with new anticancer treatments, from pathophysiology to practice: a scoping review-NEW Group (Neutropenic Events Working Group).

ABSTRACT:

Introduction

New anticancer agents are increasingly being prescribed, either in combination or as a replacement or maintenance therapy after conventional chemotherapy. Although they present certain previously unknown complications, they are also responsible for more classic hematological toxicities, such as neutropenia. Unlike conventional chemotherapy, the comprehension and management of NAN (Neutropenia Associated with Novel anticancer agent) is currently poorly codified and understood.

Methods

A literature scoping review was conducted by the NEW Group (Neutropenic Events multidisciplinary Working Group) to provide an overview of the pathophysiological mechanisms, epidemiology and management of NAN (neutropenia associated with new anticancer agents CDK4/6 inhibitors, PARP

SUBMITTER: Antherieu G 

PROVIDER: S-EPMC12672706 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature